Loading...

Friday, February 19th



Chair:
Joan Albanell, Hospital del Mar, Barcelona, Spain
16:00 - 16:20ctDNA and circulating tumor cells as predictors of relapse after neoadjuvant therapy for triple negative breast cancer
Milan Radovich, Indiana University School of Medicine, Indianapolis, USA
16:20 - 16:40Artificial Intelligence as a tool for identifying breast cancer subtypes
Maggie Cheang, The Institute of Cancer Research, London, UK
16:40 - 17:00Are current assay approval policies accurate enough? Repercussion on clinical practice
Roberto Salgado, GZA-ZNA Hospitals, Antwerp, Belgium
17:00 - 17:30Discussion
Chair:
Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain
17:45 - 18:05New drugs in metastatic HER2-positive breast cancer
Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
18:05 - 18:25Adjuvant CDK 4/6 inhibitors in operable luminal breast cancer: facts and prospects
Stephen Johnston, The Royal Marsden NHS Foundation Trust, London, UK
18:25 - 18:45HER2-low: characterization and role as a biomarker and target of therapy
Frederique Penault-Llorca, Centre Jean Perrin - Université Clermont-Auvergne, Clermont-Ferrand, France
18:45 - 19:15Discussion
Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain